Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 2
1974 2
1975 1
1980 1
1983 1
1987 1
1988 1
1990 1
2002 1
2003 1
2007 1
2008 3
2010 3
2011 4
2012 1
2014 1
2016 1
2018 2
2019 1
2020 3
2021 1
2022 1
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
Rosenberg J, Sridhar SS, Zhang J, Smith D, Ruether D, Flaig TW, Baranda J, Lang J, Plimack ER, Sangha R, Heath EI, Merchan J, Quinn DI, Srinivas S, Milowsky M, Wu C, Gartner EM, Zuo P, Melhem-Bertrandt A, Petrylak DP. Rosenberg J, et al. Among authors: merchan j. J Clin Oncol. 2020 Apr 1;38(10):1041-1049. doi: 10.1200/JCO.19.02044. Epub 2020 Feb 7. J Clin Oncol. 2020. PMID: 32031899 Free PMC article. Clinical Trial.
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.
Choueiri TK, McDermott DF, Merchan J, Bauer TM, Figlin R, Heath EI, Michaelson MD, Arrowsmith E, D'Souza A, Zhao S, Roy A, Perini R, Vickery D, Tykodi SS. Choueiri TK, et al. Among authors: merchan j. Lancet Oncol. 2023 May;24(5):553-562. doi: 10.1016/S1470-2045(23)00097-9. Epub 2023 Mar 31. Lancet Oncol. 2023. PMID: 37011650 Clinical Trial.
Renal cancer: molecular mechanisms and newer therapeutic options.
Karumanchi SA, Merchan J, Sukhatme VP. Karumanchi SA, et al. Among authors: merchan j. Curr Opin Nephrol Hypertens. 2002 Jan;11(1):37-42. doi: 10.1097/00041552-200201000-00006. Curr Opin Nephrol Hypertens. 2002. PMID: 11753085 Review.
Cognitive reserve and its correlates in child and adolescent offspring of patients diagnosed with schizophrenia or bipolar disorder.
Camprodon-Boadas P, Rosa-Justicia M, Sugranyes G, Moreno D, Baeza I, Ilzarbe D, Martínez Díaz-Caneja C, Ayora M, Merchan J, Martín N, Borras R, García-Rizo C, Torrent C, Castro-Fornieles J, de la Serna E. Camprodon-Boadas P, et al. Among authors: merchan j. Eur Child Adolesc Psychiatry. 2023 Aug;32(8):1463-1473. doi: 10.1007/s00787-022-01957-0. Epub 2022 Feb 17. Eur Child Adolesc Psychiatry. 2023. PMID: 35175425
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.
Azaro A, Massard C, Tap WD, Cassier PA, Merchan J, Italiano A, Anderson B, Yuen E, Yu D, Oakley G 3rd, Benhadji KA, Pant S. Azaro A, et al. Among authors: merchan j. Invest New Drugs. 2021 Aug;39(4):1089-1098. doi: 10.1007/s10637-021-01094-6. Epub 2021 Mar 8. Invest New Drugs. 2021. PMID: 33686452 Clinical Trial.
33 results